Side-by-side · Research reference

N-Acetyl Epitalon AmidatevsThymosin α-1

Side-by-side comparison across mechanism, dosage, evidence, side effects, administration, and stack synergies. Citations on every claim where available.

AAnimal-StrongHUMAN-REVIEWED12/45 cited

BPhase 3HUMAN-REVIEWED8/39 cited

N-Acetyl Epitalon Amidate

Bioregulator Tetrapeptide · Khavinson School

10 passagesExtra divisionsKhavinson 2004

Telomerase+Enzyme inductionKhavinson 2003

4-AATetrapeptide

SQ · Variable protocols

Thymosin α-1

Immune modulator · Approved (some countries)

1.6 mgPer doseIyer 2007

Phase 3Evidence levelIyer 2007 Camerini 2001

~2 hrHalf-life

SQ · 2× weekly · 6+ months for chronic indications

01Mechanism of Action

Parameter

N-Acetyl Epitalon Amidate

Thymosin α-1

Primary target

DNA promoter regions (telomerase, RNA polymerase II, retinal genes)

Toll-like receptor 9 (TLR9) + T-cell maturation pathwayCamerini 2001

Pathway

Peptide → DNA complementary binding → Gene transcription initiation → Telomerase catalytic subunit expression

TLR9 activation → ↑ IFN-α + IL-2 + IFN-γ → enhanced T-cell function + dendritic cell maturationIyer 2007

Downstream effect

Telomerase enzymatic activity induction, telomere elongation to early-passage length, extension of replicative lifespan in human somatic cellsKhavinson 2003 Khavinson 2004

Restored T-cell function, improved viral clearance, anti-tumour adjuvant effectsIyer 2007

Feedback intact?

—

Origin

Synthetic tetrapeptide (Ala-Glu-Asp-Gly) derived from pineal extract bioregulator research; N-acetyl and C-amide modifications enhance plasma stability

Synthetic 28-AA peptide identical to natural Tα-1 isolated from thymus extractCamerini 2001

Antibody development

—

02Dosage Protocols

Parameter

N-Acetyl Epitalon Amidate

Thymosin α-1

Standard dose

No standardized human dosing in indexed literature

In vitro protocols use direct culture addition; human clinical dosing protocols are in Russian-language literature outside PubMed scope.

—

Frequency

Not specified in candidate papers

2× weekly (Mon/Thu typical)

Evidence basis

In vitro human cell cultureKhavinson 2004 Khavinson 2003

Phase 3 + approved (35+ countries as Zadaxin)Iyer 2007

Cell culture protocol

Addition to human fetal fibroblast culture induced telomerase activity and telomere elongation to early-passage lengthKhavinson 2004

Cells made 10 extra divisions (44 passages total vs 34 in control).

—

Duration

Chronic treatment in aging culture

Sustained effect through late passages.

6–12 months for chronic indications

Modification stability

N-acetyl + C-amide caps enhance peptidase resistance

Standard strategy for tetrapeptide stabilization; specifics not quantified in candidates.

—

Standard dose (HBV/HCV)

—

1.6 mg SQ 2× weekly × 6–12 monthsIyer 2007

Lower / starter dose

—

0.8 mg per injection

Reconstitution

—

Sterile water for injection per vial label

Timing

—

No specific time

Half-life

—

~2 hours plasma; tissue effect days

04Side Effects & Safety

Parameter

N-Acetyl Epitalon Amidate

Thymosin α-1

Human safety data

Not available in indexed literature

Candidate papers describe in vitro and animal models only.

—

Theoretical telomerase risk

Telomerase activation in somatic cells raises theoretical oncogenic transformation concern

—

In vitro observations

No cytotoxicity reported in human fetal fibroblast cultureKhavinson 2004

—

Injection site reaction

—

Erythema, mild discomfort

GI symptoms

—

Rare nausea

Fatigue

—

Common during initial weeks

Fever / flu-like

—

Mild interferon-like response possible

Autoimmune

—

Theoretical risk; caution in active autoimmune disease

Cancer risk

—

No signal — used as adjuvant in oncology

Pregnancy / OB

—

Avoid

Absolute Contraindications

N-Acetyl Epitalon Amidate

·Active malignancy or history of cancer — telomerase reactivation may promote tumor cell immortalization

Thymosin α-1

·Pregnancy / breastfeeding
·Hypersensitivity to peptide
·Concurrent immunosuppressant therapy (transplant patients)

Relative Contraindications

N-Acetyl Epitalon Amidate

·Individuals with hereditary cancer syndromes or high genetic cancer risk

Thymosin α-1

·Active autoimmune disease
·Severe immunocompromised state without supervision

05Administration Protocol

Parameter

N-Acetyl Epitalon Amidate

Thymosin α-1

1. Route

Subcutaneous injection assumed based on peptide class; no specific protocol in candidate papers.

Add 1 mL sterile water per 1.6 mg vial → 1.6 mg/mL.

2. Reconstitution

Standard bacteriostatic water for lyophilized peptides. Exact volume not specified in indexed literature.

SQ — abdomen, thigh, or upper arm. Rotate sites.

3. Storage

Lyophilized: -20 °C, desiccated. Reconstituted: refrigerate 2–8 °C. N-acetyl and C-amide modifications improve stability vs unprotected tetrapeptide.

2× weekly, e.g. Monday + Thursday.

4. Clinical protocols

Human dosing schedules published in Russian-language clinical literature; not indexed in PubMed candidate set.

Lyophilised: refrigerate. Reconstituted: refrigerate, use within 24 h.

5. Needle

—

27–31G, 4–8 mm insulin syringe.

06Stack Synergy

N-Acetyl Epitalon Amidate

+ Thymalin

Moderate

View Thymalin →

Both are Khavinson-school bioregulators with epigenetic mechanisms. Thymalin targets thymic transcription factors for immune function, while Epitalon targets telomerase and pineal-axis genes. Combined use theoretically addresses dual axes of aging: replicative senescence and immune decline. Multi-target bioregulator strategy per Khavinson gerontology framework.

Epitalon: Protocol not defined in indexed literature
Thymalin: Tissue-specific bioregulator · separate dosing
Rationale: Complementary transcriptional targets
Primary benefit: Dual-axis aging intervention: cellular senescence + immune restoration

Thymosin α-1

— no documented stacks